Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

reMARQable nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

NCT01824394 is registered in ClinicalTrials.gov with Biosense Webster, Inc. as lead sponsor.

NCT NCT01824394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01824394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
reMARQable nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
Lead sponsor
Biosense Webster, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
April 1, 2013
Completion date
November 26, 2017
Enrollment
481 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation